An interventional study of Lithotripsy and Orbital atherectomy in Coronary Artery Calcification, Ischemic Heart Disease and Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), sponsored by Medical University of Silesia. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Myocardial Ischemia with a site in Poland — 4 open to participants now, 9 under way, 1 of them phase 3. Myocardial Ischemia · Poland.
Among the 35 studies in Myocardial Ischemia with a site in Poland, this one is the 27th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 32nd registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →4 of the 35 studies in Myocardial Ischemia with a site in Poland are open now. Recruiting first, the newest first:
Teleflex · Sites in Poland, United States, France and 1 more country
Ages 18–80
Medical University of Bialystok · Sites in Poland
Ages 18–75
Philips Clinical & Medical Affairs Global · Sites in Poland, United States, Australia and 15 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 6 · Phase 4 7
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 697 across the 27 interventional studies, 231 across the 8 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 35 have an industry lead sponsor. The 10 most frequent:
Medical University of Silesia is the lead sponsor of 117 studies on the registry; 28 are open to participants now.
Medical University of Silesia has 1 study filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myocardial Ischemia with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
| NCT06507449Medical University of SilesiaThe Influence of Modifying Highly Calcified Coronary Lesions on Coronary Microcirculation | 2027-08 |
| NCT07498231Medical University of BialystokCOronoary Microcirculation Analysis NETwork | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Myocardial Ischemia with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-center, three-arm study to evaluate the impact of severely calcified coronary lesions treatment on microvascular circulation. We will enroll 30 conveniently sampled subjects assigned to one of three therapeutical methods lithotripsy, super-high pressure balloon, and orbital atherectomy prior to implantation of drug-eluting stents (DES).
This prospective, non-randomized, single-center study includes subjects who meet all of the inclusion and none of the exclusion criteria and sign the ICF. 30 patients with severe coronary stenosis will be enrolled. The severity will be assessed by Optical Coherence Tomography (OCT) based on the degree of calcification in the coronary lesion as defined by this protocol. Subjects will be assigned to one of three arms (lithotripsy, super-high pressure balloon or orbital atherectomy) followed by an implantation of drug-eluting stents (DES). The aposition and expansion of DES will be evaluated using OCT . Patients will be followed through discharge, 30 days and 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Further inclusion criteria may apply
Exclusion Criteria:
Further exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The SIS Medical OPN NC® super high-pressure coronary balloon will be used for balloon angioplasty vessel preparation prior to implantation of a drug-eluting stent.
Device: High-pressure non-compliant balloon · Device: Optical coherence tomography · Device: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
Device: Orbital atherectomy · Device: Optical coherence tomography · Device: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
The Shockwave® Medical system will be used for intravascular lithotripsy (IVL) vessel preparation prior to implantation of a drug-eluting stent.
Device: Lithotripsy · Device: Optical coherence tomography · Device: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent
Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent
Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent
Optical coherence tomography assessment of coronary arteries.
A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
Coronary Flow Reserve (CFR)
Determination of a difference between Coronary Flow Reserve (CFR) at the beginning and at the end of the procedure using CoroFlow™ Cardiovascular System.
Time frame: Intraprocedural
Index of Microcirculatory Resistance (IMR)
Determination of a difference between Index of Microcirculatory Resistance (IMR) at the beginning and at the end of the procedure using CoroFlow™ Cardiovascular System.
Time frame: Intraprocedural
Stent expansion
Stent expansion (%) evaluated by optical coherence tomography.
Time frame: Intraprocedural
Acceptable stent expansion
Acceptable stent expansion (cut-off value defined as \>80%) evaluated by optical coherence tomography.
Time frame: Intraprocedural
Optimal stent expansion
Optimal stent expansion (cut-off value defined as \>90%) evaluated by optical coherence tomography.
Time frame: Intraprocedural
Minimal lumen diameter (MLD) difference
Determination of a difference between quantitative OCT measured minimal lumen diameter (MLD) at the beginning and at the end of the procedure.
Time frame: Intraprocedural
Procedural Success
Procedural success - defined as successful stent delivery and angiographic in-vessel residual stenosis \<30%, and with the absence of any of the following: stent loss, coronary artery dissection, coronary artery perforation, PCI no reflow phenomenon or MACCE (defined as a composite of cardiovascular death, myocardial infarction at the targeted vessel, targeted coronary vessel revascularization (PCI or CABG), TIA or stroke).
Time frame: Up to 3 years
Strategy Success
Strategy success - defined as procedural success without crossover to alternative treatment.
Time frame: Intraprocedural
The proportion of subjects that experience Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
30-day and 1 year MACCE defined as a composite of cardiovascular death, myocardial infarction at the targeted vessel, targeted coronary vessel revascularization (PCI or CABG), TIA or stroke.
Time frame: Up to 3 years
The proportion of subjects that experience Target Vessel Revascularization (TVR)
30-day and 1 year Target Vessel Revascularization (TVR) - defined as any repeat revascularization at the target vessel (inclusive of the target lesion) and target vessel collaterals after the completion of the procedure.
Time frame: Up to 3 years
The proportion of subjects that experience Target Lesion Revascularization (TLR)
30-day and 1 year Target Lesion Revascularization (TLR) - defined as repeat intervention PCI or surgery within the index procedure stent or 5mm proximal or distal to the stent.
Time frame: Up to 3 years
Myocardial infarction (MI) rate at 30-day and 1 year
The proportion of subjects that experience a Myocardial Infarction (MI) at 30-day and 1 year.
Time frame: Up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Aug 2027, 9 months after the start.
Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 9 months is below that.
Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2024 → Nov 2026, primary completion Jun 2026 → Aug 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Silesia →